- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sacubitril/Valsartan better than ACEI/ARB in lowering mortality risk in HFrEF patients with CKD
![Sacubitril/Valsartan better than ACEI/ARB in lowering mortality risk in HFrEF patients with CKD Sacubitril/Valsartan better than ACEI/ARB in lowering mortality risk in HFrEF patients with CKD](https://medicaldialogues.in/h-upload/2021/06/11/750x450_155808-sacubitrilvalsartan.webp)
A recent study published in the Cardiovascular Drugs and Therapy Journal found that sacubitril/valsartan has lower all-cause mortality in patients with heart failure and reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) over a 12-month follow-up period. Wei-Chieh Lee and team undertook this study to investigate the differential effects of sacubitril/valsartan and angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (ACEIs/ARBs) on clinical and renal outcomes in CKD patients HFrEF.
The study enrolled 3735 patients with HFrEF and a mean left ventricular ejection fraction of 27.56% who had been prescribed sacubitril/valsartan or ACEI/ARB. The study used propensity score matching to compare the clinical and renal outcomes between the two groups of patients with and without CKD over the 12-month follow-up period.
The highlights of the study were:
There were no significant differences in clinical and renal outcomes between the sacubitril/valsartan and ACEI/ARB groups in patients without CKD.
In the patient population that had CKD and were prescribed ACEI/ARB, the study found a 14.89% incidence of all-cause mortality over the 12-month follow-up period. On the other hand, in patients with CKD who were prescribed sacubitril/valsartan, the study found a 10.50% incidence of all-cause mortality over the same follow-up period, which was lower.
The incidence of acute kidney injury (AKI), heart failure hospitalization, and cardiovascular mortality did not differ between the two groups.
The study concludes that sacubitril/valsartan may have a lower all-cause mortality compared to ACEI/ARB in symptomatic HFrEF patients with CKD. However, the Authors of this study also noted that further prospective randomized studies are warranted to confirm these findings.
Source:
Lee, W.-C., Liao, T.-W., Chen, T.-Y., Fang, H.-Y., Fang, Y.-N., Chen, H.-C., Lin, Y.-S., Chang, S.-H., & Chen, M.-C. (2023). Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease. In Cardiovascular Drugs and Therapy. Springer Science and Business Media LLC. https://doi.org/10.1007/s10557-022-07421-0
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751